SEARCH

SEARCH BY CITATION

References

  • 1
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 2
    Barcena R, Del Campo S, Sanromán AL et al. Prospective study of hepatitis C virus infection after orthotopic liver transplantation. Transplant Proc 1997; 29: 515516.
  • 3
    Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: Persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000; 6: 4453.
  • 4
    Prieto M, Berenguer M, Rayon J et al. High incidence of allograft cirrhosis in HCV genotype 1b following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250256.
  • 5
    Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830836.
  • 6
    Berenguer M, Prieto M, San Juan F et al. Contribution of donors age to the recent decrease in percents survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 7
    Sanchez Fueyo A, Restrepo JC, Quinto L et al. Impact of recurrence of hepatitis C virus infection after liver transplantation on the long term viability of the graft. Transplantation 2002; 73: 5663.
  • 8
    Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673684.
  • 9
    Wali M, Harrison RF, Gow PJ, Mutimer DJ. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248252.
  • 10
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825832.
  • 11
    Feray C, Samuel D, Gigou M et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995; 22: 10841089.
  • 12
    Samuel D, Bizollon T, Feray C et al. Interferon alfa 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomised study. Gastroenterology 2003; 124: 642650.
  • 13
    Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 14
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. Hepatology 2004; 39: 11471171.
  • 15
    Barcena R, Gil-Grande L, Moreno J et al. Partial esplenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin. Transplantation 2005; 79: 16341635.
  • 16
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 17
    Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533541.
  • 18
    Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004; 77: 190194.
  • 19
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669674.
  • 20
    Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 21
    Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-alfa in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577582.
  • 22
    Shergill AK, Khalili M, Straley S et al. Applicability tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118124.
  • 23
    Babatin M, Schindel L, Burak KW. Pegylated interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359365.
  • 24
    Biselli M, Andreone P, Gramenzi A et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liv Dis 2006; 38: 2732.
  • 25
    Oton E, Barcena R, Garcia-Garzon S et al. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant Proc 2005; 37: 39633964.
  • 26
    Sheiner PA, Boros P, Klion FM et al. The efficacy of prophylactic interferon alfa 2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831838.
  • 27
    Singh N, Gayowski T, Wannstedt CF et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant patients: a prospective randomized controlled trial. Transplantation 1998; 65: 8286.
  • 28
    Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005; 41: 289298.
  • 29
    Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (alfa-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 5359.
  • 30
    Ross AS, Bhan AK, Pascual M, Thiim M, Cosimi AB, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166173.
  • 31
    Moreno A, Barcena R, Garcia-Garzon S et al. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected and liver transplanted patients on peg-IFN-α-2b/ribavirin. J Hepatol 2005; 43: 783790.
  • 32
    Saab S, Kalmaz D, Gajjar NA et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859867.
  • 33
    Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003; 44: 471475.
  • 34
    Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: Coincidence or true side effect?. Cancer 1999; 85: 25832588.
  • 35
    Durand JM, Quiles N, Kaplanski G, Soubeyrand J. Thrombosis and recombinant interferon-alpha. Am J Med 1993; 95: 115116.
  • 36
    Biselli M, Lorenzini S, Gramenzi A et al. Hepatic artery stenosis in liver transplanted patients treated with pegylated interferon alpha-2b and ribavirin. Transplantation 2004; 78: 953.
  • 37
    Kovarik J, Mayer G, Pohanka E et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alfa treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45: 402405.
  • 38
    Kramer P, Ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 989990.
  • 39
    Bizollon T, Palazzo U, Ducerf C et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500504.
  • 40
    Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis following liver transplantation. Liver Transpl 2004; 10: 850858.
  • 41
    Bizollon T, Pradat P, Mabrut JY et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transpl 2005; 5: 19091913.
  • 42
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 10001006.
  • 43
    Bizollon T, Ahmed SNS, Radenne S et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283287.
  • 44
    Nakagawa M, Sakamoto N, Tanabe Y et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 10311041.
  • 45
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 12821288.
  • 46
    Firpi RJ, Zhu H, Morelli G et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 5157.
  • 47
    Hunt J, Gordon FD, Lewis WD et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: Influence of immunosuppressive regimens. Liver Transpl 2001; 7: 10561063.
  • 48
    Papatheodoridis GV, Davies S, Dhillon AP et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72: 412418.
  • 49
    Testa G, Crippin JS, Netto GJ et al. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553561.
  • 50
    Chopra KB, Demetris AJ, Blakolmer K et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003; 76: 14871491.
  • 51
    Samonakis DN, Triantos CK, Thalheimer U et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386395.
  • 52
    Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226231.